![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky
Received October 7, 2005; accepted December 9, 2005.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
activates 
-catenin/T-cell factor (Tcf)/lymphoid enhancer factor (Lef) pathway through phosphorylation of glycogen synthase kinase (GSK)-3. TP agonist [1S-,2(Z),3(1E,3S),4]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (I-BOP) induced both and forms of GSK-3 phosphorylation in human embryonic kidney (HEK)293 cells stably overexpressing TP (HEK293-TP). N-[2-(4-Bromocinnamylamino)ethyl]-5-isoquinoline (H89), a protein kinase A (PKA) inhibitor, totally blocked the phosphorylation of GSK-3, whereas wortmannin, a phosphatidylinositol 3-kinase (PI-3 kinase) inhibitor, partially attenuated it, suggesting that PKA as well as PI-3 kinase/Akt pathway were involved in TP-induced phosphorylation of GSK-3. I-BOP consistently stimulated an approximately 8-fold increase over basal Tcf/Lef reporter gene activity in HEK293-TP cells. Furthermore, I-BOP-induced Tcf/Lef reporter gene activity was totally inhibited by H89 and partially inhibited by wortmannin. I-BOP also induced overexpression of Tcf/Lef downstream target gene cyclin D1. Blockade of the -catenin expression by small interfering RNA approach attenuated I-BOP-induced expression of cyclin D1, indicating that the induction was mediated by -catenin/Tcf/Lef pathway. Finally, I-BOP resulted in the morphology change, such as cell rounding and aggregation, in HEK293-TP cells after 1-h incubation. However, HEK293-TP cells were not able to revert back to normal shape even 24 h after the removal of the agonist, suggesting that the prolonged activation of the Tcf/Lef promoter induced downstream gene expression leading to cell permanent morphology change that was related to cell transformation. Together, our results showed for the first time TP agonist-induced phosphorylation of GSK-3 and activation of Tcf/Lef signaling leading to cell proliferation and transformation.
and TP, have been recognized. They differ in their carboxyl-terminal tails and their mechanisms of desensitization and internalization (Kinsella, 2001
). TP is known to couple to multiple G proteins, including Gq/11, G12/13, Gi, Gs, and Gh, and mediates many cellular responses (Halushka et al., 1995). One of the notable responses is the stimulation of mitogenic and hypertrophic growth of vascular smooth muscle. For example, U-46619, a TP agonist, stimulates the proliferation of rat coronary or aortic smooth muscle cells (Smith, 1992) and enhances the mitogenic effects of classic growth factors such as platelet-derived growth factor and basic fibroblast growth factor (Ali et al., 1993; Zhao and Foegh 1997). I-BOP, another TP agonist, triggers a protein kinase C (PKC)-, pertussis toxin-, Src-, and epidermal growth factor receptor (EGFR)-dependent activation of extracellular signal-regulated kinase (ERK) in a human endothelial cell line, ECV304 (Gao et al., 2001). U-46619 was also reported to induce c-Jun NH2-terminal kinase activation and protein kinase A (PKA)-dependent cyclooxygenase-2 (COX-2) expression in porcine aortic smooth muscle cells (McGinty et al., 2000). Recently, Gallet et al. (2003) demonstrated that TP agonist-dependent transactivation of EGFR was mediated partially by matrix metalloproteinases and subsequent activation of ERK in human aortic smooth muscle cells. Stimulation of cell proliferation by TP agonists was observed beyond vascular smooth cells. Lin et al. (2005) reported that U-46619 stimulated the proliferation of oligodendrocyte progenitor cells and promoted the survival of mature oligodendrocyte in central nervous system. It seems that TP-mediated cell proliferation and survival are mainly dependent on two interactive pathways: one pathway is through transactivation of EGFR leading to phosphorylation of ERK; another pathway is activation of PKA-dependent pathway.
Some GPCRs are known to functionally link to T-cell factor (Tcf)/-catenin signaling pathway. Activation of mouse F9 clones expressing the chimera receptor constructed from the 2 adrenergic receptor and the Frizzled-1 receptor with the -adrenergic agonist isoproterenol stimulated stabilization of -catenin, activation of a -catenin-sensitive promoter, and formation of primitive endoderm (Liu et al., 2001). Thereafter, it was shown that activation of FPB, an isoform of prostaglandin F2 receptor, led to a decrease in the phosphorylation of cytoplasmic -catenin and a stimulation of Tcf/Lef-mediated transcriptional activation (Fujino and Regan, 2001). The same group also demonstrated the activation of the Tcf/Lef signaling pathway through EP receptors, EP2 and EP4, using stably transfected receptor in HEK293 cells (Fujino et al., 2002). Recently, GPCR and Tcf/Lef cross-talk was expanded to colon cancer cells. Yang et al. (2005) showed that activation G protein-coupled lysophosphatidic acid receptors stimulated proliferation of colon cancer cells through the -catenin pathway and induced cell proliferation.
An important enzyme in the -catenin/Tcf signaling pathway is glycogen synthase kinase-3 (GSK-3) (Doble and Woodgett, 2003). This enzyme is responsible for the phosphorylation and degradation of -catenin through ubiquitin proteosome pathway. Two isoforms of GSK-3, GSK-3 and GSK-3, encoded by two distinct genes have been identified (Woodgett, 1990; Hoeflich et al., 2000). GSK-3 is well known to be phosphorylated by Wnt signal mediated by frizzled receptor (Nelson and Nusse, 2004). GSK-3 also can be phosphorylated by Akt/PKB, PKC, and PKA (Fang et al., 2002). Direct inhibition of the GSK-3 either by its inhibitors or by phosphorylation prevents the phosphorylation and degradation of -catenin. Stabilized -catenin accumulates in the cytosolic compartment of the cell, translocates to the nucleus, and binds to members of Tcf/Lef transcriptional factors and induces expression of several downstream genes that have important roles in the development and progression of carcinoma, including cyclin D1, c-myc, vascular endothelial growth factor, COX-2, matrix metalloproteinase 7, urokinase-type plasminogen activator, and CD44 (Wong and Pignatelli, 2002).
Since TP can activate Akt/PKB, PKC, and PKA (Miggin and Kinsella, 2002), we propose that there is a possible cross-talk between the TP and the Tcf/Lef signaling pathway. Using HEK293 cells stably transfected with TP gene, we report here that the stimulation of TP by its agonist I-BOP led to GSK-3 phosphorylation, Tcf/Lef signaling activation, and permanent cell morphology change. These effects seem to be related to cell transformation.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
-catenin antibody were obtained from Sigma-Aldrich (St. Louis, MO). Mouse monoclonal antibody specific to pERK, and -catenin siRNA and control siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Rabbit polyclonal antibody specific to pGSK-3/ was from Cell Signaling Technology Inc. (Beverly, MA). FuGENE6 was from Roche Diagnostics (Alameda, CA). pcDNA3 encoding TP and rabbit polyclonal antibody specific to N-terminal sequence of the TP were generated as described previously (Zhou et al., 1999). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were prepared as described previously (Wu et al., 1997). Rabbit monoclonal antibody specific to cyclin D1 was provided by Lab Vision (Fremont, CA). Horseradish peroxidase-linked goat anti-mouse and rabbit IgG were supplied by BD Transduction Laboratories (Lexington, KY). The HEK293 cell lines were supplied by the American Type Culture Collection (Manassas, VA). ECL Western blotting detection was supplied by the Amersham Pharmacia Biotech (Cardiff, UK). The Tcf/Lef reporter plasmids kit including TOP flash, containing two sets (with the second set in the reverse orientation) of the three copies of the Tcf site upstream of the luciferase open reading frame, and FOP flash, containing mutated Tcf elements, served as a background and was purchased from Upstate Biotechnology (Lake Placid, NY).
Cell Culture and Stable Transfectants. HEK293 cells were cultured as monolayer in DMEM supplemented with 10% heat-inactivated FBS, gentamicin, and antibiotic-antimycotic at 37°C in a humidified atmosphere of 95% air and 5% CO2. The cells were subcultured in six-well plates or 12-well plates to achieve 80% confluence on the next day, and then the cells were transfected with pcDNA3-TP using LipofectAMINE reagent. For stable transfection, the cells were allowed to grow in 10% FBS medium for 48 h after transfection and then the cells were diluted 10-fold and treated with 1 mg/ml Geneticin (G418) until the colonies formed as described previously (Zhou et al., 1999). The Western blot detection of the TP and the [3H]SQ-29548 binding assay of the receptor were used to monitor the expression level among the different colonies. After the colony with a high level of expression of TP was obtained, it was maintained in DMEM media supplemented with 10% heat inactivated FBS and 200 µg/ml G418.
Whole-Cell Radioligand Binding Assay. Cells were cultured in 10-cm plates and were harvested when 90% confluence was achieved. The cells were washed in ice-cold phosphate-buffered saline buffer three times. Then, 1 x 106 cells were resuspended in 95 µl of phosphate-buffered saline buffer using 1.5-ml plastic tubes, and the binding assay was conducted in the same tubes. The total volume of the reaction was 100 µl, which contained [3H]SQ-29548 with the concentration from 2.6 x 10–12 to 2.6 x 10–7 M. The nonspecific binding was determined under the same conditions except 10 µM SQ-29548 was added to the reaction mixture. The binding reaction was performed at room temperature for 1 h and was terminated by placing the tubes on ice for 10 min. The cell suspension was then filtered under vacuum through a GF/C glass filter followed by washing three times. The radioactivity retained on the filter was counted in 10 ml of scintillation cocktail. The Kd and Bmax were calculated using nonlinear regression method by GraphPad Prism 4.01 (Graph-Pad Software Inc., San Diego, CA).
Western Blot Analysis. Cells were cultured in six-well plates to achieve approximately 80% confluence. For ERK and GSK-3 activation, the cells were starved in DMEM media without FBS for 16 h, and then cells were challenged by 50 nM I-BOP for 15 min to achieve significant phosphorylation of ERK, and for 0 to 60 min to monitor the time course of the activation of GSK-3/. For inhibition study, various inhibitors were preincubated with cells for 20 min following treatment with I-BOP for 15 min. Cells were harvested and lysed in lysis buffer (1% Nonidet P-40 in 150 mM NaCl, 50 mM HEPES, pH 7.4, 5 mM NaF, 5 mM pyrophosphate, 1 mM sodium orthovanadate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride) for 1 h on ice. Lysate was cleared by centrifugation at maximum speed on a benchtop centrifuge and then subjected to 12% SDS-PAGE. Proteins were then electrophoretically transferred onto PVDF membrane. The membrane was blocked with 5% nonfat milk in 30 mM Tris-HCl, pH 7.4, containing 120 mM NaCl (TBS) at room temperature for 1 h. It was then incubated for 2 h at room temperature with a primary antibody in TBS with 5% nonfat milk, and then the membrane was washed three times with TBS buffer containing 0.05% Tween 20, following incubation with horseradish peroxidase-linked goat anti-mouse or rabbit IgG for 1 h at room temperature. Finally, the membrane was washed with TBS buffer containing 0.05% Tween 20 three times. The immunoreactive bands were detected using ECL Western blotting detection system.
Tcf/Lef Reporter Gene Assay. HEK293-TP cells were grown in six-well plates and transiently transfected with 1 µg/well of either TOP flash or FOP flash plasmids using FuGENE6 procedure as described in the manufacturer's protocol. Cells were preincubated with inhibitors at indicated concentrations or vehicle (0.1% dimethyl sulfoxide) for 20 min at 37°C followed by challenging with 50 nM I-BOP or vehicle for 1 h at 37°C. Cells were then washed three times each with 1 ml/well of FBS-free DMEM media and then incubated with FBS-free DMEM media for 16 h at 37°C. Cell lysate was prepared for luciferase assay. Luciferase activity was measured using a microplate luminometer with 5 µg of protein per sample. The specific reporter gene activity was corrected for background activity by subtraction of FOP flash values from corresponding TOP flash values.
siRNA Treatment. Cells were transiently transfected with -catenin siRNA at the concentration of 20 pmol/well in 12-well plates using LipofectAMINE reagent. The cells were treated with the siRNA for 48 h to achieve the maximal blockade of the expression of the -catenin.
Phase-Contrast Microscope. For phase-contrast microscopic studies, HEK293 or HEK293-TP cells were grown in 12-well plates to achieve approximately 40 to 50% confluence using DMEM media containing 10% FBS and the same antibiotics as mentioned above. Cells were visualized under phase-contrast microscope using a Zeiss Axiovert S100 inverted microscope. Images were captured using a Kodak digital camera.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
stably transfected cells since it has minimal basal expression of TP. As shown in Fig. 1A, Western blotting using antibody specific to N-terminal peptide of TP demonstrated that HEK293-TP expressed significantly TP compared with HEK293 cells transfected with vector alone. Similar to previous reports, HEK293-TP had a high affinity to TP antagonist SQ-29548, with a Kd value of 14.6 ± 1.4 nM and Bmax value of 5.3 ± 0.31 pmol/mg protein characterized by [3H]SQ-29548 binding assay (Fig. 1B). The functional assay of the TP was characterized by agonist-stimulated ERK activation. As shown in Fig. 1C, the TP agonist I-BOP stimulated significant phosphorylation of ERK in HEK293-TP cells, whereas minimal response was observed in HEK293 cells transfected with vector alone. TP agonist-induced activation of ERK has been well documented in several cell lines (Gao et al., 2001; Miggin and Kinsella, 2001). Our results are consistent with previous reports and provide evidence that HEK293-TP cells expressed functionally active TP.
|
TP Agonist-Stimulated Phosphorylation of GSK-3/ in HEK293-TP Cells. Previous reports showed that several prostaglandins such as PGE2 and PGF2 could induce phosphorylation of GSK-3/ through their specific receptors (Fujino et al., 2002; Shao et al., 2005). We used HEK293-TP cells to study GSK-3/ phosphorylation upon TP agonist stimulation. As shown in Fig. 2A, both GSK-3 and GSK-3 were phosphorylated in 2 min following exposure to 50 nM I-BOP in HEK293-TP cells. Phosphorylation of GSK-3/ was achieved maximally at 5 min after stimulation by I-BOP and was gradually decreased during the following 50 min. The time-course studies showed that phosphorylation of GSK-3/ still persisted at high level even after 60 min of incubation with I-BOP, indicating that the signal induced by a TP agonist existed for a relatively long time. However, no detectable phosphorylation of GSK-3/ was found in HEK293 cells (data not shown). As shown in Fig. 2B, I-BOP induced phosphorylation of GSK-3/ in a concentration-dependent manner. I-BOP at 1 nM clearly led to phosphorylation of GSK-3/ and phosphorylation reached to a maximum at 50 nM. We then used the specific kinase inhibitors to determine which pathway(s) was involved in the GSK-3/ phosphorylation. As shown in Fig. 2C, PKA inhibitor H89 not only totally blocked I-BOP-induced GSK-3/ phosphorylation but also inhibited basal level of pGSK-3/, suggesting that PKA is required to maintain the pGSK-3/ in unstimulated cells. TP antagonist SQ-29548 can block I-BOP-induced phosphorylation of GSK-3/, suggesting that the signal transduction is directly through TP. A concentration-dependent inhibition by H89 is shown in Fig. 2D. However, wortmannin, an inhibitor of PI-3 kinase, partially blocked GSK-3/ phosphorylation. Surprisingly, the well known PKC activation following TP activation was not involved in this process, since its inhibitor GF109203X had no effect on I-BOP-induced GSK-3/ phosphorylation.
|
-Catenin Accumulation in Cytoplasmic Fraction and Tcf/Lef Reporter Gene Activation following Stimulation of TP. Phosphorylation of GSK-3/ is known to inactivate GSK-3/. Consequently, I-BOP-induced phosphorylation of GSK-3/ may stimulate accumulation of -catenin in the cytosolic compartment and enhance translocation of -catenin from the cytosol to the nucleus, leading to the Tcf/Lef transcription factor activation. As shown in Fig. 3, I-BOP induced an increase in the amount of -catenin in the cytosolic fraction of HEK293-TP cells. I-BOP consistently stimulated an 8-fold increase in the Tcf/Lef reporter gene expression in HEK293-TP cells as shown in Fig. 4. Since H89 and wortmannin were found to block I-BOP-induced GSK-3/ phosphorylation, they were also used to examine the effect on the activation of the Tcf/Lef reporter gene expression. As shown in the same figure, I-BOP-induced activation of the Tcf/Lef reporter gene was totally blocked by H89 and partially blocked by wortmannin, but it was not affected by GF compound. Again, the TP antagonist SQ-29548 can block the TCF/Lef activation. This is consistent with the results of GSK-3/ phosphorylation induced by I-BOP in HEK293-TP cells. It is clear that I-BOP activates Tcf/Lef transcription factor through GSK-3/ phosphorylation and that PKA and PI-3 kinase/Akt pathways were involved in this process. However, TP coupled to Gq, leading to PKC activation had no direct effect on this process in our system.
|
|
|
Cells upon TP Agonist Stimulation. Previous reports demonstrated that -catenin regulated cyclin D1 expression (Tetsu and McCormick, 1999). -Catenin/TCF/Lef complex could bind to cyclin D1 promoter to modulate cell cycle progression and proliferation. In HEK293-TP cells, I-BOP caused a rapid and persistent (up to 8 h) increase in cyclin D1 expression (Fig. 5A). Inhibition of -catenin expression by siRNA approach as indicated in Fig. 5B attenuated I-BOP-induced cyclin D1 expression as shown in Fig. 5C. Control siRNA had no effect.
|
Cells following Stimulation by TP Agonist. Activation of -catenin/TCF/Lef is often linked to cell phenotypic transformation leading to developmental or malignant transformation. Cell morphology change in HEK-TP cells began to show after 30 min of incubation with I-BOP and was clearly observed following 1 h of incubation as shown in Fig. 6. Incubation of I-BOP for 1 h resulted in cell rounding and aggregation in HEK293-TP cells (Fig. 6A, c and d), whereas I-BOP had no effect on HEK293 cells transfected with pcDNA3 vector alone under the same conditions (Fig. 6A, a and b). After 1-h incubation with I-BOP, the HEK293-TP cells were washed with DMEM without FBS to remove I-BOP, but the cells could not revert back to the normal shape even after 24 h (Fig. 6B, a and b), suggesting that a short time incubation with TP agonist was sufficient to induce a permanent change in cell morphology. The permanent morphology change is likely the consequence of the agonist-induced gene expression mentioned above. It may be recalled that in the Tcf/Lef reporter gene assay, H89 and wortmannin had an inhibitory effect on the activation of Tcf/Lef. In accordance with this, preincubation of HEK293-TP cells with H89 (Fig. 7, E and F) prevented the I-BOP-induced cell morphology change, whereas wortmannin (Fig. 7, G and H) and GF109203X (Fig. 7, I and J) had little preventive effect. Blockade of the TP signaling by antagonist SQ-29548 could prevent I-BOP-induced permanent cell morphology change, suggesting that the TP was directly involved in the signal transduction leading to cell transformation.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
to study the signaling mechanism and its relevance to cell transformation. We demonstrated that the activation of TP led to GSK-3 phosphorylation, T-cell factor signaling activation, and cell morphology change. A detailed scheme depicting the signaling pathway of TP activation is summarized in Fig. 8. Previous report indicated that two isoforms of TP may be coupled differentially to Gs and Gi (Hirata et al., 1996). TP is coupled to Gs, leading to an increase in intracellular level of cAMP and activation of PKA, whereas TP is coupled to Gi, leading to a decrease in intracellular level of cAMP. It seems that the activation of Tcf/Lef pathway by TP is mainly mediated by a PKA-dependent mechanism. A reasonable prediction is that TP may not induce the activation of Tcf/Lef pathway or TP activation of Tcf/Lef pathway is mediated by other mechanism(s). It has been shown that the activation of both EP2 and EP4 may induce the stimulation of Tcf/Lef pathway. Activation of Tcf/Lef pathway by EP2 was shown to be mediated by a PKA mechanism, whereas stimulation of Tcf/Lef pathway by EP4 was demonstrated to be mediated by a PKB/Akt mechanism (Fujino et al., 2002). This is because activation of EP2 induces a significantly higher level of intracellular cAMP compared with that of EP4 (Fujino et al., 2002). Whether the activation of TP may lead to the stimulation of Tcf/Lef pathway or other pathway(s) involved in the activation of Tcf/Lef needs to be elucidated in TP stably transfected cells.
|
/, activation of Tcf/Lef signaling, and cell morphology change in TP stably transfected HEK293 cells. Similar results were obtained with U-46619, another stable agonist of TP, in these cells. Furthermore, we also observed I-BOP-induced rapid phosphorylation of GSK-3/ and activation of Tcf/Lef signaling in human lung cancer A549 cells (data not shown). Previously, it was also shown that the activation of EP2 and EP4 led to significant phosphorylation of GSK-3 but not that of GSK-3 (Fujino et al., 2002). However, in our studies both forms of GSK-3 were rapidly phosphorylated upon stimulation of TP. The difference in response is not clear and needs to be further explored. In addition to cAMP/PKA pathway, we also found that PI-3 kinase inhibitor wortmannin partially inhibited phosphorylation of GSK-3/. The activation of Akt/PKB by TP agonists was reported previously by Miggin and Kinsella (2002). Akt/PKB is known to be one of upstream kinases of GSK-3 inducing phosphorylation and inhibition of GSK-3 (Cross et al., 1995). In fact, Akt/PKB-dependent activation of the -catenin/Tcf pathway was reported in ECV304 carcinoma cells (Maupas-Schwalm et al., 2005). One possible explanation is that PKA is an upstream kinase of Akt/PKB pathway and may indirectly phosphorylate GSK-3/ (Filippa et al., 1999). This may account for why H89 totally blocked the phosphorylation of GSK-3, whereas wortmannin partially attenuated it.
The accumulation of -catenin in the cytosol is a direct result from the phosphorylation and inhibition of GSK-3/, as shown in this study. Intracellular -catenin level, however, can be regulated by other pathways as well. It is known that Wnt signaling also regulates intracellular -catenin level. A large multiprotein complex that includes proteins of the Adenomatous polyposis coli and Axin families normally facilitates the phosphorylation of -catenin by GSK-3 (Nelson and Nusse, 2004). Phosphorylated -catenin is then rapidly degraded by the ubiquitin-mediated proteosome pathway. When Wnt signal is absent, the signal transduction pathway is off because -catenin is rapidly destroyed. When cells are exposed to Wnt signal, it binds to cell surface receptors of the Frizzled family. Receptor activation antagonizes the Adenomatous polyposis coli-Axin "destruction complex" by an unknown mechanism that seems to be mediated by the Dishevelled protein. This blocks the phosphorylation of -catenin and its subsequent degradation. Unphosphorylated -catenin forms a pool in the cytosol and then translocates to the nucleus where it activates the genes regulated by Tcf/Lef transcription factors. Our findings and reports of studies on other GPCRs such as EP2 and FPB expanded the Wnt pathway to other signaling pathways that could directly phosphorylate and inactivate the GSK-3/ and regulate -catenin level.
The linkage between -catenin and cyclin D1 was established from accumulated reports especially in human cancers (Utsunomiya et al., 2001). The cyclin D1 is associated with cancer growth, invasion, and metastasis through influencing the cell cycle progression. We show here that I-BOP stimulates overexpression of cyclin D1, and blockade of -catenin expression by siRNA approach attenuates this effect. Furthermore, our preliminary data showed that TP agonist stimulated a permanent change in cell morphology, such as cell rounding and aggregation. A same phenomenon was found in the activation of FP receptors stably transfected in HEK293 cells (Fujino and Regan, 2001). In this report, FPB isoform that activated the Tcf/Lef transcription factors induced a permanent change in cell morphology, whereas FPA, which could not activate Tcf/Lef, only caused a temporary change in cell morphology. A previous report showed that overexpression of COX-2 and microsomal prostaglandin E synthase had the potential to affect cellular proliferation and morphology change (Murakami et al., 2000). Many studies demonstrated that expression of COX-2 is associated with cell proliferation, antiapoptosis, and differentiation (Mann et al., 2001). As mentioned in previous reports, a permanent change in cell morphology was an indication of developmental or malignant transformation. Thromboxane A2 is one of the downstream metabolites of COX-2 and is involved the proliferation of several cell lines. It also has roles in the tumor growth and metastasis (Daniel et al., 1999; Nie et al., 2000; Pradono et al., 2002). Therefore, our findings have expanded COX-2/PGE2 pathway to COX-2/thromboxane A2 pathway. To verify the possible roles of TP in cancer, lung cancer A549 cells stably overexpressing TP receptor and lung cancer H157 cells stably transfected with TP siRNA were prepared. Preliminary data indicated that I-BOP induced COX-2 expression in A549 cells overexpressing TP, suggesting that a positive feedback might occur in COX-2- and TP-expressing cells. Generation of tumors in the nude mice using these cell lines is currently in progress in our laboratory.
|
Footnotes |
|---|
ABBREVIATIONS: TP, thromboxane receptor; GPCR, G protein-coupled receptor; U-46619, 9,11-methanoepoxy-PGF2; I-BOP, [1S-,2(Z),3(1E,3S),4]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid; PKC, protein kinase C; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; PKA, protein kinase A; COX, cyclooxygenase; Tcf, T-cell factor; Lef, lymphoid enhancer factor; EP, prostaglandin E2 receptor; HEK, human embryonic kidney; FP, prostaglandin F2 receptor; GSK-3, glycogen synthase kinase-3; PKB, protein kinase B; FBS, fetal bovine serum; SQ-29548, 7-[(1S,2R,3R,4R)-3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-, (5Z)-(9CI); H89, N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline; GF109203X, 3-[1-[3-(dimethylaminopropyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione monohydrochloride; pERK, phosphorylated extracellular signal-regulated kinase; siRNA, small interfering RNA; pGSK, phosphorylated glycogen synthase kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; DMEM, Dulbecco's modified Eagle's medium; PAGE, polyacrylamide gel electrophoresis; PVDF, polyvinylidene difluoride; TBS, Tris-buffered saline; PG, prostaglandin.
Address correspondence to: Dr. Hsin-Hsiung Tai, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0082. E-mail: htai1{at}uky.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Ali S, Davis MG, Becker MW, and Dorn GW 2nd (1993) Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem 268: 17397–17403.
Cross DA, Alessi DR, Cohen P, Andjelkovich M, and Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (Lond) 378: 785–789.[CrossRef][Medline]
Daniel TO, Liu H, Morrow JD, Crews BC, and Marnett LJ (1999) Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59: 4574–4577.
Doble BW and Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175–1186.
Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, and Mills GB (2002) Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22: 2099–2110.
Filippa N, Sable CL, Filloux C, Hemmings B, and Van Obberghen E (1999) Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol 19: 4989–5000.
Fujino H, West KA, and Regan JW (2002) Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem 277: 2614–2619.
Fujino H and Regan JW (2001) FP prostanoid receptor activation of a T-cell factor/beta–catenin signaling pathway. J Biol Chem 276: 12489–12492.
Gallet C, Blaie S, Levy-Toledano S, and Habib A (2003) Epidermal-growth-factor receptor and metalloproteinases mediate thromboxane A2-dependent extracellular signal-regulated kinase activation. Biochem J 371: 733–742.[CrossRef][Medline]
Gao Y, Tang S, Zhou S, and Ware JA (2001) The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src dependent phosphorylation of the epidermal growth factor receptor. J Pharmacol Exp Ther 296: 426–433.
Halushka PV, Allan CJ, and Davis-Bruno KL (1995) Thromboxane A2 receptors. J Lipid Mediat Cell Signal 12: 361–378.[CrossRef][Medline]
Hirata T, Ushikubi F, Kakizuka A, Okuma M, and Narumiya S (1996) Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Investig 97: 949–956.[Medline]
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, and Woodgett JR (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature (Lond) 406: 86–90.[CrossRef][Medline]
Kinsella BT (2001) Thromboxane A2 signalling in humans: a `tail' of two receptors. Biochem Soc Trans 29: 641–654.[CrossRef][Medline]
Lin X, Ramamurthy SK, and Le Breton GC (2005) Thromboxane A receptor-mediated cell proliferation, survival and gene expression in oligodendrocytes. J Neurochem 93: 257–268.[CrossRef]
Liu T, DeCostanzo AJ, Liu X, Wang HY, Hallagan S, Moon RT, and Malbon CC (2001) G protein signaling from activated rat frizzled-1 to the -catenin-Lef-Tcf pathway. Science (Wash DC) 292: 1718–1722.
Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, and DuBois RN (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120: 1713–1719.[CrossRef][Medline]
Maupas-Schwalm F, Robinet C, Auge N, Thiers JC, Garcia V, Cambus JP, Salvayre R, and Negre-Salvayre A (2005) Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells. Cancer Res 65: 526–532.
McGinty A, Foschi M, Chang YW, Han J, Dunn MJ, and Sorokin A (2000) Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades. Biochem J 352: 419–424.[Medline]
Miggin SM and Kinsella BT (2001) Thromboxane A(2) receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells. Biochim Biophys Acta 1539: 147–162.[Medline]
Miggin SM and Kinsella BT (2002) Regulation of extracellular signal-regulated kinase cascades by alpha-and beta-isoforms of the human thromboxane A2 receptor. Mol Pharmacol 61: 817–831.
Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, et al. (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275: 32783–32792.
Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y, and Honn KV (2000) Thromboxane A2 regulation of endothelial cell migration, angiogenesis and tumor metastasis. Biochem Biophys Res Commun 267: 245–251.[CrossRef][Medline]
Nelson WJ and Nusse R (2004) Convergence of Wnt, beta-catenin and cadherin pathways. Science (Wash DC) 303: 1483–1487.
Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, and Nukiwa T (2002) Gene transfer of thromboxane A2 synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62: 63–66.
Shao J, Jung C, Liu C, and Sheng H (2005) Prostaglandin E2 stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 280: 26565–26572.
Smith WL (1992) Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263: F181–F191.[Medline]
Tetsu O and McCormick F (1999) beta-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (Lond) 398: 422–426.[CrossRef][Medline]
Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, Sekimoto M, Tamura S, Yasuda T, Fujiwara Y, and Monden M (2001) Correlation of beta-catenin and cyclin D1 expression in colon cancers. Oncology 61: 226–233.[CrossRef][Medline]
Wong NA and Pignatelli M (2002) beta-Catenin–a linchpin in colorectal carcinogenesis. Am J Pathol 160: 389–401.
Woodgett JR (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO (Eur Mol Biol Organ) J 9: 2431–2438.[Medline]
Wu P, Hou WM, and Tai HH (1997) NAD+-dependent glyceraldehydes-3-phosphate dehydrogenase is a novel substrate for cholera and pertussis toxins in human platelet cytosol. Res Commun Cell Biol Biochem 1: 21–32.
Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T, and An S (2005) G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci USA 102: 6027–6032.
Zhao Y and Foegh ML (1997) Angiopeptin, a somatostatin analogue, inhibits rat coronary artery and aorta smooth muscle cell proliferation induced by the thromboxane A2 mimetic U46619. Prostaglandins 54: 781–793.[CrossRef][Medline]
Zhou H, Yan F, and Tai HH (1999) Phosphorylation and desensitization of the human thromboxane receptor- by G-protein-coupled receptor kinases. J Pharmacol Exp Ther 298: 1243–1251.
This article has been cited by other articles:
|
|
 |
|
  S. Gardner, S. Maudsley, R. P. Millar, and A. J. Pawson Nuclear Stabilization of {beta}-Catenin and Inactivation of Glycogen Synthase Kinase-3{beta} by Gonadotropin-Releasing Hormone: Targeting Wnt Signaling in the Pituitary Gonadotrope Mol. Endocrinol., December 1, 2007; 21(12): 3028 - 3038. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
